EIKN's Quality Score rose 1 point on Tue, Nov 10, to 0. Its high and its low were both higher than the day before.
New listing, trading since Feb 5, 2026. 193 trading days so far, so 1 of the 14 chart checks waits for more history.
Follow EIKN's trial news. Pro members can get an alert when Eikon Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 4.4% today, while its biotech peers are down 1.4%; no story names it yet.
Fell on Oct 26
Down 24% on Oct 26, and still 19% under its Oct 23 close.
“Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress.”
−2Volatility
| Holding it back | Moves 10.7% a day with no profit behind it |
| Latest filing | 8-K, Oct 26 |
TodayNo story names it yet.
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
1 more date ahead: the IPO anniversary, for Pro members.
After its last 3 reports it closed +7.2% on average, higher 2 of 3 times.
$531M in cash
No shelf registration or at-the-market program on file in the last three years.
Director Kenneth C Frazier bought 111,111 shares on Feb 4. 1 more insider trade this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
EIKN is #145 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 145 |
Reports Thu Nov 12, after the close (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease was primarily due to the impairment in the year-ago period of $10.7 million of property and equipment and $10.3 million of operating lease right-of-use assets relating to properties in Hayward, California that Eikon vacated in April 2025 when the Company moved into its current corporate headquarters in Millbrae, California.”
EIKN's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 13, 2026 | +3.8% | +7.0% | +4.1% |
| May 11, 2026 | +6.1% | +15.9% | +18.1% |
| Mar 30, 2026 | -0.1% | -1.3% | -3.8% |
RSI 43.2, MACD above signal. Not scored.
One insider bought $1M across 1 filing in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: EIKN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
Listed on Nasdaq on Feb 5, 2026, and is 66% below its $18 offer price now. Its IPO filing and first days
EIKN scores 0 today, which Breakaway calls Below Average. It is #145 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 24% on Oct 26, and still 19% under its Oct 23 close. Shares: 19.0 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
EIKN scores 0 today, which Breakaway calls Below Average (0 to 5). That is #145 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind EIKN's 0.
One insider bought $1M across 1 filing in the last 6 months. No open-market sales on record. The newest is Column Group IV GP, LP, 10% owner, who bought $1M on Sep 3.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.